-+ 0.00%
-+ 0.00%
-+ 0.00%

NextCure publishes corporate presentation on Phase 1 antibody-drug conjugate cancer programs

PUBT·05/07/2026 21:11:53
Listen to the news
NextCure publishes corporate presentation on Phase 1 antibody-drug conjugate cancer programs
  • NextCure outlined development plans for SIM0505, a CDH6-targeting antibody-drug conjugate licensed ex-China from Simcere Zaiming, with Phase 1 trials running in China and US.
  • Initial Phase 1 summary as of April 16, 2025 showed 5 patients treated across 1.6 mg/kg (n=3) and 3.2 mg/kg (n=2), with no dose-limiting toxicities reported to date.
  • Early activity included a partial response at 1.6 mg/kg in serous endometrial carcinoma, with a 43% reduction in target lesions at first 6-week assessment.
  • Next milestone flagged as Phase 1 clinical data in 2Q 2026, followed by a trial progress update in 2H 2026.
  • Presentation also highlighted LNCB74, a B7-H4-targeting MMAE ADC in Phase 1 under a 50/50 co-development partnership with LigaChem Biosciences.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NextCure Inc. published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.